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Abstract
Background: This study was aimed at determining the effects and safety of Da-Cheng-Qi decoction (DCQD) or DCQD combined with
conservative therapy in patients with intestinal obstruction.
Materials and Methods: PubMed, EMBASE, Cochrane Controlled Trials Register, and several other databases were searched. Randomised
controlled trials (RCTs) of DCQD or DCQD plus conservative therapy in patients with intestinal obstruction were eligible. Therapeutic effect was
estimated by the improvement of clinical manifestations and diagnostic imaging; dichotomous/ordinal data assessment of overall response to
therapy, adverse effects; or continuous variable were identified, including time to first bowel movement, time to first flatus, length of hospital
stay.
Results: Sixty eligible RCTs including 6,095 patients were identified. Response rate: (1) DCQD versus conservative therapy (6 RCTs, 361
patients, RR of respond =1.13; 95% CI 0.97 to 1.31). (2) DCQD plus conservative therapy versus conservative therapy (48 RCTs, 4,916 patients,
RR of respond =1.25 which favoured DCQD plus conservative therapy; 95% CI 1.20 to 1.30). Treatment effect remained similar when RCTs at
high risk of bias were excluded. Time to first flatus postoperatively: (1) DCQD versus conservative therapy (2 RCTs, 240 patients, SMD=-3.65;
95% CI -8.17 to 0.87). (2) DCQD plus conservative therapy versus conservative therapy (11 RCTs, 1,040 patients, SMD=-2.09 which favoured
DCQD plus conservative therapy; 95% CI -3.04 to -1.15).
Conclusion: DCQD combined with conservative therapy may increase the success rate of conservative therapy for intestinal obstruction
significantly and can shorten the duration of postoperative ileus in patients undergoing abdominal surgery compared with conservative therapy
alone.
Key words: Da-Cheng-Qi-Tang; Intestinal Obstruction; Ileus; Intestinal Pseudo-Obstruction; Meta-Analysis.
Introduction
Intestinal obstruction refers to any impairment, arrest, or reversal of the normal flow of intestinal contents toward the anal canal. It can be
classified according to pathogenesis: ileus (a transient impairment of bowel motility caused by operation, inflammation, metabolism, neurogenic
reasons and drugs) and mechanical intestinal obstruction (a kind of obstruction caused by any mechanical reasons, such as adhesion, neoplasm or
herniation. And it accounts for approximately 15% of all emergency department visits for acute abdominal pain (Williams et al., 2005)).
Postoperative ileus and mechanical intestinal obstruction caused by postoperative adhesions are the predominant types respectively.(Moran, 2007;
Kumar et al., 2009) For ileus, conservative therapy containing bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics and sometimes cathartics are the main strategies of treatment. As for mechanical intestinal obstruction, surgery is warranted in patients
with obstruction when conservative therapy does not resolve within 48 hrs after it initiated (Fevang et al., 2002). Conservative therapy has been
shown to be successful in more than 70% of the patients with mechanical intestinal obstruction (Tanaka et al., 2008). However, delay in diagnosis
and suitable treatment may cause a substantial increase of complications. The complications of intestinal obstruction include bowel ischemia and
perforation, which may lead to severe outcomes or even death. (Markogiannakis et al., 2007) The diagnosis and treatment of intestinal obstruction
remains a challenge.
Da-Cheng-Qi decoction (DCQD), Dai-joki-to in Japanese, a classic Chinese herbal formula (Satoh, 2013), is commonly used for the treatment
of intestinal obstruction besides modern medicine in Chinese hospitals (Qi et al, 2004). The main components of DCQD are Radix et Rhizoma
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Rhei, Cortex Magnoliae Officinalis, Fructus Aurantii Immaturus and Natrii Sulfas. Herbs in formula can sometimes be slightly adjusted (jiajian
in Chinese pinyin) by doctor’s judgments about the patients’ clinical manifestations. DCQD can be administered via oral or rectal, and is to be
stopped if patients egrets. Though pharmacological studies have shown different positive effects of the single plant extracts in DCQD,(Xu et al.,
2010; Tang et al., 2008; Qi et al., 2007; Gong et al., 2011) as a formula, efficacy or side-effects of DCQD has not been systematically assessed till
now. Therefore, the objective of the systematic review and meta-analysis is to determine the effects (benefits and harms) of DCQD in the
treatment of intestinal obstruction, in mono-therapy or in combination with conservative therapy, as compared to conservative therapy alone.
Methods
Search strategy and study selection.
A search of the medical literature was conducted using PubMed (up to July 2011), EMBASE (1980 to July 2011), Cochrane Controlled
Trials Register (issue 7, 2011), Sinomed (up to July 2011), China National Knowledge Infrastructure (CNKI) database (1994 to July 2011),
Wanfang Data (1989 to July 2011) and the VIP Information (1990 to July 2011). Randomised Controlled Trials (RCTs) comparing the effects of
DCQD or DCQD plus conservative therapy with conservative therapy in adult patients with intestinal obstruction (ileus or mechanical) were
eligible for inclusion. Trials using other pharmaco-therapies were eligible, as long as these were administered to both the intervention and control
groups. Diagnosis of intestinal obstruction could be based on case history, clinical manifestations and diagnostic imaging (X-ray or computed
tomography scan). The primary outcome of this meta-analysis was estimated by the improvement of clinical manifestations (relief of abdominal
pain, passage of flatus/stool, bowel movement) and diagnostic imaging (X-ray or computed tomography scan). We attempted to contact the
original investigators in order to obtain further information if necessary. Studies on intestinal obstruction were identiﬁed with the terms intestinal
obstruction; intestinal pseudo-obstruction and ileus, (both as medical subject heading (MeSH) and free text terms), small bowel obstruction, SBO
and large bowel obstruction (as free text terms). These were combined using the set operator AND, with studies identiﬁed using the terms: 
Da-Cheng-Qi-Tang, DCQT herbal medicine and Drugs, Chinese Herbal (MeSH terms), Da-Cheng-Qi decoction (free text terms). We also
searched the reference lists of the original reports, reviews, letters to the editor, case reports and meta-analyses of studies involving Chinese
herbal medicine (retrieved through the electronic searches) to identify studies which had not yet been included in the computerised databases, all
potentially relevant papers were obtained and evaluated in detail. There were no language restrictions. Articles were independently assessed by
two reviewers (YB and XFY) using predesigned eligibility criteria: 1) randomised controlled trials; 2) diagnosis of intestinal obstruction based on
case history, clinical manifestations and diagnostic imaging (X-ray or computed tomography scan); 3) interventions: DCQD or DCQD plus
conservative therapy compared with conservative therapy (DCQD jiajian was allowed); 4) decoction administered via oral and/or rectal; 5)
therapeutic effect was estimated by the improvement of clinical manifestations (relief of abdominal pain, passage of flatus/stool, bowel movement)
and/or diagnostic imaging (X-ray or computed tomography scan); 6) dichotomous/ordinal data assessment of overall response to therapy, adverse
effects; or continuous variable were identified, including time to first flatus, time to first bowel movement, length of hospital stay. Any
disagreement between reviewers was resolved by consensus between the two reviewers (YB and XFY), adjudicated with the support of a third
reviewer (SHJ).
Outcome assessment
The primary outcome assessed was the obstruction cured or improvement at the end of treatment. Failure to response to therapy was defined
as no improvement in clinical manifestations (ileus) or as needing surgical treatment (mechanical). If ordinal data were given to define
obstruction improvement, they were transformed into dichotomous data (e.g. if the scale was 1, no improvement (ileus) or needs surgical
treatment (mechanical); 2, a little improvement; 3, a moderate amount of improvement; 4, great improvement; the latter 3 descriptors were
defined as positive outcomes). Secondary outcomes considered was continuous data defined as time to first flatus.
Data extraction
All data were extracted independently by two reviewers (Y.B. and SHJ) onto a pre-designed form (Microsoft Office Excel 2007; Microsoft
Corp, Redmond, Washington, USA). All data extraction was then checked by a third reviewer (ZZ). The following data were extracted for each
trial: number of centres; geographical location of the study; study population; sample size; proportion of female patients; criteria used to define
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intestinal obstruction; aetiology (including detailed abdominal operation histories); the route of administration; duration of treatment; concomitant
medications allowed; total number of adverse events reported; primary outcome measure used to define clinical manifestations improvement or
cure following treatment; duration of follow-up; method used to generate the randomization schedule and conceal allocation. Data were extracted
as intention-to-treat analyses, where all drop-outs were assumed to be treatment failures, wherever trial reporting allowed this.
Assessment of risk of bias
Assessment of risk of bias was performed independently by two reviewers (YB and SHJ), with disagreements resolved by discussion. Risk
of bias was assessed according to the elaborated CONSORT checklist for herbal interventions (Gagnier et al., 2006, 2006) by recording
characteristics of the herbal product, qualitative testing, dosage regimen and quantitative description, method used to generate the randomization
schedule and conceal allocation, whether blinding was implemented, what proportion of patients completed follow-up, and whether an
intention-to-treat analysis was extractable etc.. 2-properly with detailed description, 1-mentioned but not detailed reported, 0-not mentioned or
inappropriate. A trial with a quality score ≤ 18 was considered as a trial at high risk of bias, and a trial with a quality score ≥ 36 was considered as 
a trial at low risk of bias, the left were at moderate risk of bias.
Data synthesis and statistical analysis
Data were pooled using a random effects model to produce wider confidence intervals and more conservative estimates.(DerSimonian et al.,
1986) The impacts of DCQD on dichotomous outcomes were expressed as a relative risk (RR) of response to therapy with intervention compared
with control with 95% confident intervals (CIs). The number needed to treat (NNT) with 95% CIs were calculated from the reciprocal of the risk
difference of the meta-analysis. Time to first flatus was examined using a standardised mean difference (SMD) with a 95% CI.
Heterogeneity between studies was assessed using the I2 statistic with a cut-off of > 50% to define a significant degree of heterogeneity. We
conducted a pre-specified sensitivity analyses according to the type of intestinal obstruction, risk of bias of identified trials, detailed operation
histories, the route of administration and the definition of response to therapy. These were exploratory analyses only, and may explain some of the
observed variability, the results, however, should be interpreted with caution.
Review Manager Version 5.0 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) and Stata/SE version 10.0 (StataCorp, College
Station, Texas, USA), were used to generate forest plots for outcomes with 95% CIs, as well as funnel plots. The latter were assessed for evidence
of asymmetry, and possible publication bias or other small study effects were evaluated using the Begg’s test. (Begg et al., 1994)
Results
The search strategy initially yielded 752 citations, 109 of which appeared to be relevant to the systematic review and were retrieved for
further assessment (Figure 1). Of these, 49 were excluded for various reasons, leaving a total of 60 eligible articles. Seven RCTs compared the
effect of DCQD with conservative therapy, 54 compared the effect of DCQD plus conservative therapy with conservative therapy alone.
Characteristics of the included trials were shown in supplementary Tables.
DCQD versus conservative therapy
The seven RCTs comparing DCQD with conservative therapy involved a total of 521 patients. Five trials were at moderate and two trials
were at high risk of bias according to the modified elaborated CONSORT statement for herbal interventions. The pathogenesis in six RCTs was
ileus while it was incomplete mechanical intestinal obstruction in one trial. Dichotomous data could be extracted from six RCTs. There were 24
(13.2%) of 182 patients assigned to DCQD who failed to respond to therapy, compared with 38 (21.2%) of 179 allocated to conservative therapy
(RR of respond=1.13; 95% CI 0.97 to 1.31) (Fig 2). There was borderline heterogeneity between studies (I2=58%), with no statistically significant
funnel plot asymmetry (Begg’s test, p=1.00) suggesting no evidence of publication bias or other small study effects
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Figure 1: Flow diagram of RCTs included
Table 1: Sensitivity analyses of efficacy of DCQD in intestinal obstruction
Number of studies Number of subjects RR 95% CI I2 value NNT 95% CI
All studies# 6 361 1.13 0.97 to 1.31 58% N/A N/A
Risk of bias of trials
Moderate 5 301 1.14 0.95 to 1.39 66% N/A N/A
High 1 60 1.08 0.88 to 1.32 N/A N/A N/A
Route of administration
Via oral 4 231 1.08 0.84 to 1.39 67% N/A N/A
Via rectal 2 130 1.22 0.93 to 1.59 70% N/A N/A
Deﬁnition of response to therapy
Clinical alone 4 301 1.07 0.91 to 1.25 65% N/A N/A
Clinical + Imaging 2 60 1.45 1.11 to 1.91 0% 3.2 2 to 7.7
Aetiology
Postoperative 3 190 1.15 1.01 to 1.31 35% 7.7 4.2 to 50
Non-postoperative 3 171 1.11 0.72 to 1.73 78% N/A N/A
N/A, not applicable; # refers to the studies dichotomous data can be extracted from.
Response to therapy in patients with ileus
The five trials studying ileus reported dichotomous data of 301 patients. Overall, ileus was caused by operation in 190 patients. 21 (13.8%)
of 152 patients assigned to DCQD failed to respond to therapy compared with 33 (22.1%) of 149 patients allocated to conservative therapy (RR
of respond =1.14; 95% CI 0.95 to 1.39). There was significant heterogeneity between studies (I2=66%) with no evidence of funnel plot
asymmetry (Begg’s test, p=0.73). Two RCTs reported continuous data of the time to first flatus post-operatively. There was no statistical
difference when results of individual RCTs were combined (SMD=-3.65; 95% CI -8.17 to 0.87) (Figure 3), and there was significant
heterogeneity among these two studies (I2=99%).
Response to therapy in patients with mechanical intestinal obstruction
Only one trial containing 60 patients studied incomplete mechanical intestinal obstruction, 3 (10.0%) of 30 patients assigned to DCQD
failed to respond to therapy compared with 5 (16.7%) of 30 patients allocated to conservative therapy (RR of respond =1.08; 95% CI 0.88 to 1.32)
(Figure 2).
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Sensitivity analysis
Given the borderline heterogeneity observed when results of individual RCTs were combined, we conducted pre-specified sensitivity
analyses (Table 1). The RR of respond was relatively stable in these analyses. Heterogeneity between trials was lower and 95% CI doesn’t include
the number “1” when only the two studies that used clinical manifestations and imaging improvement to define response to therapy were included
in the analysis. Treatment effect remained similar when only the five trials at low risk of bias were considered.
DCQD plus conservative therapy versus conservative therapy
The 54 RCTs comparing DCQD plus conservative therapy with conservative therapy contained a total of 5,574 patients with intestinal
obstruction. 27 trials were at moderate and 27 trials were at high risk of bias. Twenty-one RCTs studied ileus while 33 studied mechanical
intestinal obstruction. Dichotomous data could be extracted from 48 RCTs. There were 221 (8.4%) of 2,641 patients assigned to DCQD plus
conservative therapy who failed to respond to therapy, compared with 648 (28.5%) of 2,275 allocated to conservative therapy alone (RR of
respond=1.25; 95% CI 1.20 to 1.30 which favoured DCQD plus conservative therapy), with borderline heterogeneity between studies (I2=55%)
(Fig 4) and an NNT of 5.3 (95% CI 4.8 to 6.3). There was no statistically significant funnel plot asymmetry (Begg’s test, p=0.31) suggesting no
evidence of publication bias or other small study effects.
Response to therapy in patients with ileus
In the 21 trials studying ileus, 15 reported dichotomous data in 1,168 patients. Overall, ileus of 879 patients was caused by operation. Fifty-one
(8.4%) of 606 patients assigned to DCQD plus conservative therapy failed to respond to therapy compared with 150 (26.7%) of 562 patients
allocated to conservative therapy (RR of respond =1.23; 95% CI 1.13 to 1.34 which favoured DCQD plus conservative therapy) (Fig 4), with
significant heterogeneity between studies (I2=67%) and an NNT of 5.9 (95% CI 4.3 to 9.1). There was no evidence of funnel plot asymmetry
(Begg’s test, p=0.19).
Eleven RCTs reported continuous data of time to first flatus post-operatively. There was statistical difference when results of individual RCTs
were combined (SMD=-2.09; 95% CI -3.04 to -1.15 which favoured DCQD plus conservative therapy) (Fig 3), and there was significant
heterogeneity among studies (I2=97%).
Table 2: Sensitivity analyses of efficacy of DCQD plus conservative therapy in intestinal obstruction
Number of studies Number of subjects RR 95% CI I2 value NNT 95% CI
All studies# 48 4,916 1.25 1.20 to 1.30 55% 5.3 4.8 to 6.3
Risk of bias of trials
Moderate 23 1,996 1.24 1.16 to 1.33 69% 5.6 4.5 to 7.7
High 25 2,920 1.26 1.21 to 1.31 18% 5 4.3 to 5.9
Route of administration
Via oral 22 2,231 1.22 1.16 to 1.28 33% 5.9 5 to 7.7
Via rectal 12 1,072 1.32 1.24 to 1.39 0% 4.2 3.6 to 5.3
Oral and rectal 14 1,613 1.24 1.13 to 1.36 77% 5.6 4.2 to 9.1
Deﬁnition of response to therapy 
Clinical alone 11 1,136 1.30 1.19 to 1.41 48% 4.8 3.7 to 6.3
Clinical + Imaging 37 3,780 1.24 1.18 to 1.29 55% 5.6 4.8 to 6.7
Aetiology
Postoperative 35 3,724 1.22 1.17 to 1.27 53% 5.9 5 to 7.1
Non-postoperative 13 1,192 1.34 1.24 to 1.45 31% 4.2 3.6 to 5
# refers to the studies dichotomous data can be extracted from
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Supplementary Table 1: Characteristics of the included RCTs (part A)
trials
DOI definition of intestinal
obstruction
aetiolo
gy
clinical background
female
patients
number of
participants
averag
e age
route of DCQD
administration
duration of
treatment
duration of
follow-up
Ao XR
2007
CNKI:SUN:JXZY.0.200
7-07-039
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 44 96 44.4
(nasogastric
tube/oral) and rectal
5d N/A
Cao SB
2008
CNKI:SUN:SXZY.0.20
08-09-031
diagnostic imaging +
clinical manifestations
ileus N/A 26 69 71.1 rectal 7d N/A
Chen CQ
2002
cnki:ISSN:1009-9727.0.
2002-03-017
clinical manifestations
alone
ileus stroke 71 180 58.5 nasogastric tube/oral 14d N/A
Chen H
2009
CNKI:SUN:CZXX.0.20
09-04-045
diagnostic imaging +
clinical manifestations
mecha
nical
N/A 24 65 42.24 nasogastric tube/oral 78h N/A
Chen ZJ
2004
cnki:ISSN:1005-7331.0.
2004-02-027
clinical manifestations
alone
mecha
nical
abdominal surgery 15 50 50.8 rectal 5d N/A
Dong ZC
2008
CNKI:SUN:SXZY.0.20
08-05-026
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 27 68 56.9
(nasogastric
tube/oral) and rectal
10d N/A
Dou WH
2009
CNKI:SUN:SHIX.0.200
9-07-019
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 34 80 41.8 nasogastric tube/oral 10d N/A
Fan Y
2007
CNKI:ISSN:1003-5699.
0.2007-03-019
clinical manifestations
alone
mecha
nical
abdominal surgery N/A 60 N/A nasogastric tube/oral 48h N/A
Fang HL
2008
CNKI:SUN:GAYX.0.20
08-04-076
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 267 538 N/A
(nasogastric
tube/oral) and rectal
N/A N/A
Fu HB
2008
CNKI:SUN:BHON.0.20
08-03-026
diagnostic imaging +
clinical manifestations
ileus stroke 27 62 63.5 nasogastric tube/oral 3d N/A
Gao JC
2005
cnki:ISSN:1000-3649.0.
2005-01-017
clinical manifestations
alone
ileus abdominal surgery 12 42 39 nasogastric tube/oral 7d 1y
Gao ZJ
2010
CNKI:SUN:SXZY.0.20
10-09-034
diagnostic imaging +
clinical manifestations
ileus
abdominal neoplasm or
peritonitis
15 60 51.75 nasogastric tube/oral 21d N/A
He GM
2009
CNKI:SUN:ZDYS.0.20
09-21-060
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 50 97 40.6 nasogastric tube/oral 7d N/A
Hu ZG CNKI:SUN:HNZG.0.20 diagnostic imaging + mecha N/A 59 126 52.5 (nasogastric 48h 1-5y
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2008 08-04-030 clinical manifestations nical tube/oral) and rectal
Jiang CL
2008
CNKI:SUN:HNZY.0.20
08-07-048
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 58 110 34.6 rectal N/A N/A
Jiang K
2009
CNKI:SUN:LZXB.0.20
09-04-071
diagnostic imaging +
clinical manifestations
ileus abdominal surgery 23 50 41.5 rectal N/A N/A
Li H 2010
CNKI:SUN:GSZY.0.20
10-05-015
diagnostic imaging +
clinical manifestations
ileus abdominal surgery 25 56 36.1 nasogastric tube/oral 7d N/A
Li HS
2004
cnki:ISSN:1004-745X.0.
2004-08-022
clinical manifestations
alone
mecha
nical
N/A 50 212 30.9 rectal 48h 6-72m
Li HY
2006
N/A clinical manifestations
alone
ileus abdominal surgery 160 160 28.5 nasogastric tube/oral N/A N/A
Li R 2007
CNKI:ISSN:1006-978X.
0.2007-01-010
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 24 56 41 rectal 15d N/A
Li ZY
2006
cnki:ISSN:1000-7369.0.
2006-01-038
clinical manifestations
alone
ileus abdominal surgery 15 50 48.7 rectal 72h N/A
Liang QF
2004
cnki:ISSN:0256-7415.0.
2004-07-025
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 29 51 36.9 rectal 3d N/A
Liang
WH 2010
CNKI:SUN:YYXK.0.20
10-20-028
diagnostic imaging +
clinical manifestations
ileus abdominal surgery 35 68 41.85 nasogastric tube/oral 7d N/A
Liao DX
2009
CNKI:SUN:SXLC.0.200
9-28-022
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 52 136 N/A nasogastric tube/oral N/A 1m
Liao ZY
2006
cnki:ISSN:1008-2409.0.
2006-04-043
clinical manifestations
alone
ileus abdominal surgery 28 80 37.5 rectal 99h N/A
Liu JS
1996
N/A clinical manifestations
alone
mecha
nical
abdominal surgery 19 36 32.7
(nasogastric
tube/oral) and rectal
N/A N/A
Liu P
2009
CNKI:SUN:ZGSQ.0.20
09-19-173
clinical manifestations
alone
ileus abdominal surgery N/A 207 N/A rectal N/A 0.5-1y
Liu Q
2009
N/A
clinical manifestations
alone
ileus N/A 33 60 53.5 nasogastric tube/oral N/A N/A
Liu XH
2005
cnki:ISSN:1003-7705.0.
2005-01-009
diagnostic imaging +
clinical manifestations
ileus abdominal surgery 24 50 50.7 rectal 35d 114m
Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119
http://dx.doi.org/10.4314/ajtcam.v11i4.17
108
Lu YH
2008
CNKI:SUN:ZWYY.0.20
08-07-050
diagnostic imaging +
clinical manifestations
mecha
nical
N/A 44 96 50 nasogastric tube/oral 7d N/A
Luo M
2005
cnki:ISSN:1007-6948.0.
2005-01-011
clinical manifestations
alone
ileus abdominal surgery 41 97 40.4 rectal N/A 1-1.5y
Ma ZJ
2005
cnki:ISSN:0256-7415.0.
2005-07-015
clinical manifestations
alone
ileus
fracture thoracic vertebrae or
lumbar vertebrae
20 60 N/A nasogastric tube/oral 6d N/A
Peng T
2010
CNKI:SUN:YXSS.0.201
0-09-244
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 35 116 42.4 nasogastric tube/oral 7d N/A
Qiu JF
2009
CNKI:SUN:XXYY.0.20
09-06-049
clinical manifestations
alone
ileus abdominal surgery 21 60 51.7 nasogastric tube/oral N/A N/A
Shen JQ
2005
cnki:ISSN:1005-4561.0.
2005-10-005
diagnostic imaging +
clinical manifestations
ileus
abdominal surgery,
gastrointestinal neoplasm
20 56 34.8
(nasogastric
tube/oral) and rectal
18d N/A
Su SH
2008
CNKI:SUN:QKYX.0.20
08-22-032
diagnostic imaging +
clinical manifestations
ileus N/A 6 15 N/A nasogastric tube/oral 7d N/A
Sui J
2010
CNKI:SUN:SYYZ.0.20
10-12-078
diagnostic imaging +
clinical manifestations
mecha
nical
N/A 43 108 51.2
(nasogastric
tube/oral) and rectal
7d N/A
Sun JJ
2006
cnki:ISSN:1000-7369.0.
2006-01-037
clinical manifestations
alone
ileus abdominal surgery 155 302 67.8 nasogastric tube/oral N/A N/A
Tang ZA
2008
CNKI:SUN:SYLC.0.200
8-11-065
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 21 60 41.5
(nasogastric
tube/oral) and rectal
10d N/A
Tao YJ
2008
CNKI:SUN:XDJH.0.200
8-21-058
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 64 170 46.1 nasogastric tube/oral 4d N/A
Tong FG
2006
N/A clinical manifestations
alone
mecha
nical
N/A 22 64 N/A nasogastric tube/oral 3d N/A
Wang CG
2010
CNKI:SUN:JYGZ.0.201
0-02-032
diagnostic imaging +
clinical manifestations
ileus abdominal surgery 15 38 31.7
(nasogastric
tube/oral) and rectal
10d N/A
Wang CH
2009
CNKI:SUN:HNZY.0.20
09-06-017
clinical manifestations
alone
ileus abdominal surgery 150 150 44.8 nasogastric tube/oral 2d N/A
Wang P
2007
CNKI:ISSN:1004-0501.
0.2007-05-042
diagnostic imaging +
clinical manifestations
mecha
nical
tuberculous peritonitis 36 65 38.6 rectal 72h N/A
Wang W cnki:ISSN:1671-4040.0. diagnostic imaging + mecha abdominal surgery 56 162 N/A nasogastric tube/oral N/A N/A
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2004 2004-03-014 clinical manifestations nical
Wang YF
2009
CNKI:SUN:PTGZ.0.200
9-05-009
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 70 127 49 nasogastric tube/oral N/A N/A
Wen JY
2008
CNKI:SUN:ZWYY.0.20
08-05-038
diagnostic imaging +
clinical manifestations
ileus abdominal surgery 13 32 40.2 rectal N/A N/A
Wu CT
2003
cnki:ISSN:1001-5426.0.
2003-02-011
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 58 248 40.9 nasogastric tube/oral 24h N/A
Wu DH
2009
CNKI:SUN:FJZY.0.200
9-06-030
clinical manifestations
alone
mecha
nical
abdominal surgery 20 52 51.5 rectal 7d N/A
Xie ZC
2008
CNKI:SUN:YLQY.0.20
08-06-061
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 59 125 37.5 rectal N/A N/A
Xu HY
2009
CNKI:SUN:MZMJ.0.20
09-20-045
diagnostic imaging +
clinical manifestations
ileus abdominal surgery 25 80 63.9 nasogastric tube/oral 10d N/A
Yang SZ
2010
CNKI:SUN:JLYX.0.201
0-31-027
clinical manifestations
alone
ileus abdominal surgery 14 42 53.6
(nasogastric
tube/oral) and rectal
N/A N/A
Ye B
2008
N/A diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 43 70 N/A
(nasogastric
tube/oral) and rectal
5d N/A
You L
2008
CNKI:SUN:SJZX.0.200
8-04-025
clinical manifestations
alone
mecha
nical
phytobezoar induced
obstruction
35 96 37.3 nasogastric tube/oral 3d N/A
Zhang Y
2007
CNKI:ISSN:0256-7415.
0.2007-01-006
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 41 97 38.8
(nasogastric
tube/oral) and rectal
5d N/A
Zhao Y
2006
cnki:ISSN:0256-7415.0.
2006-03-029
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 44 117 43.9
(nasogastric
tube/oral) and rectal
3-5d N/A
Zhao YL
2006
N/A clinical manifestations
alone
ileus abdominal surgery 82 162 46.1 nasogastric tube/oral N/A N/A
Zheng
HL 2010
CNKI:SUN:GDYY.0.20
10-04-071
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 40 100 46.5
(nasogastric
tube/oral) and rectal
72h N/A
Zhou SY
2009
CNKI:SUN:GYZX.0.20
09-04-022
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 40 86 44.5
(nasogastric
tube/oral) and rectal
24h N/A
Zhou YJ
2001
cnki:ISSN:1004-745X.0.
2001-06-016
diagnostic imaging +
clinical manifestations
mecha
nical
abdominal surgery 16 78 45.8
(nasogastric
tube/oral) and rectal
N/A N/A
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Supplementary Table 2: Characteristics of the included RCTs (part B)
Trials Interventions (experimental group) Interventions (control group) Outcomes
Ao XR 2007 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, laxatives (liquid paraffin), soapsuds enema, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, laxatives (liquid
paraffin), soapsuds enema
improvement of clinical/imaging manifestations
Cao SB 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation
improvement of clinical/imaging manifestations
Chen CQ
2002#
1) DCQD jiajian 2) cisapride 3*10mg/d, DCQD jiajian cisapride 3*10mg/d time to first stool, length of hospital stay
Chen H 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
DCQD jiajian 50mL/6h
bowel rest, intubation and decompression, intravenous
fluid resuscitation antibiotics
time to first flatus, time to clinical/imaging manifestations
improved, time to extubation, length of hospital stay
Chen ZJ 2004 bowel rest, decompression, antibiotics, intravenous fluid resuscitation,
DCQD 200ml/12h
bowel rest, decompression, antibiotics, intravenous fluid
resuscitation
time to first stool, improvement of clinical manifestations
Dong ZC 2008 bowel rest, decompression, intravenous fluid resuscitation, DCQD
175ml/12h, antibiotics
bowel rest, decompression, intravenous fluid
resuscitation, soapsuds enema
improvement of clinical/imaging manifestations
Dou WH 2009 bowel rest, decompression, antacid, intravenous fluid resuscitation,
antibiotics, DCQD 200ml/24h
bowel rest, decompression, antacid, intravenous fluid
resuscitation, antibiotics
improvement of clinical/imaging manifestations
Fan Y 2007 DCQD 200ml/24h cisapride 3*5mg/d time to first bowel movement, improvement of clinical
manifestations
Fang HL 2008 bowel rest, decompression, intravenous fluid resuscitation, antibiotics,
DCQD 200-300ml/24h
bowel rest, decompression, intravenous fluid
resuscitation, antibiotics
time to first stool, improvement of clinical/imaging
manifestations
Fu HB 2008 bowel rest, decompression, intravenous fluid resuscitation, antibiotics,
DCQD 200ml/24h
bowel rest, decompression, intravenous fluid
resuscitation, antibiotics
time to first stool, improvement of clinical/imaging
manifestations
Gao JC 2005 decompression, intravenous fluid resuscitation, antibiotics, DCQD decompression, intravenous fluid resuscitation,
antibiotics
time to first flatus, improvement of clinical manifestations
Gao ZJ 2010 bowel rest, intubation and decompression, intravenous fluid resuscitation,
total parenteral nutrition, glucocorticoids, antibiotics, DCQD jiajian
100ml/12h, metoclopramide 10mg
bowel rest, intubation and decompression, intravenous
fluid resuscitation, total parenteral nutrition,
glucocorticoids, antibiotics
improvement of clinical/imaging manifestations, length of
hospital stay
He GM 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
total parenteral nutrition, glucocorticoids, antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, total parenteral nutrition,
improvement of clinical/imaging manifestations, length of
hospital stay
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200ml/24h glucocorticoids, antibiotics
Hu ZG 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
total parenteral nutrition, coloclysis with physiological saline, DCQT
jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, total parenteral nutrition, coloclysis
with physiological saline
improvement of clinical/imaging manifestations
Jiang CL 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
total parenteral nutrition, antibiotics, coloclysis with 200ml DCQT
jiajian(twice/day)
bowel rest, intubation and decompression, intravenous
fluid resuscitation, total parenteral nutrition, antibiotics,
coloclysis with 200ml physiologic saline (twice/day)
improvement of clinical/imaging manifestations
Jiang K 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
somatostatin, histamine 2 blocking pharmacon, glucocorticoids, DCQD
jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, somatostatin, histamine 2 blocking
pharmacon, glucocorticoids
improvement of clinical/imaging manifestations
Li H 2010 bowel rest, intubation and decompression, intravenous fluid resuscitation,
proton pump inhibitor, glucocorticoids, antibiotics, diuretic, DCQD
jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, proton pump inhibitor,
glucocorticoids, antibiotics, diuretic
improvement of clinical/imaging manifestations, time to
first flatus, time to first bowel movement, time to first
stool, the duration of treatment
Li HS 2004 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian 100ml(2 times/day),
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
time to first stool, improvement of clinical manifestations
Li HY 2006 DCQD jiajian bowel rest, intubation and decompression, intravenous
fluid resuscitation
time to first flatus
Li R 2007 bowel rest, intubation and decompression, intravenous fluid resuscitation,
somatostatin, histamine 2 blocking pharmacon, antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, somatostatin, histamine 2 blocking
pharmacon, antibiotics
improvement of clinical/imaging manifestations, length of
hospital stay
Li ZY 2006 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD 200ml (twice/day)
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
time to first flatus, time to first stool, the gastrin level
change, the vascular intestinal peptide(VIP) level
Liang QF 2004 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian 200ml (twice/day)
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
Liang WH
2010
bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, glucocorticoids, somatostatin, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, glucocorticoids,
somatostatin
time to first flatus, time to first stool, time to
clinical/imaging manifestations improved, time to
imaging improvement
Liao DX 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, somatostatin, acupuncture moxibustion, DCQD jiajian,
change position continuously
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, somatostatin, change
position continuously
improvement of clinical/imaging manifestations
Liao ZY 2006 intubation and decompression, intravenous fluid resuscitation, antibiotics, intubation and decompression, intravenous fluid improvement of clinical manifestations, time to first
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DCQD resuscitation, antibiotics, coloclysis with glycerol flatus, time to first stool, time to clinical manifestations
improved
Liu JS 1996 intubation and decompression, intravenous fluid resuscitation, antibiotics,
DCQD
intubation and decompression, intravenous fluid
resuscitation, antibiotics
time to first flatus, time to first stool, time to recovery of
body temperature, length of hospital stay, complications
Liu P 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, vitamin B1, DCQD
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, vitamin B1
improvement of clinical manifestations
Liu Q 2009 antibiotics, DCQD intubation and decompression, intravenous fluid
resuscitation, antibiotics
improvement of clinical manifestations
Liu XH 2005 bowel rest, intravenous fluid resuscitation, intubation and decompression,
antibiotics, glucocorticoids, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, laxatives (glycerol, liquid
paraffin or castor oil)
improvement of clinical/imaging manifestations
Lu YH 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
Luo M 2005 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
first bowel movement, time to first flatus, time to first
stool
Ma ZJ 2005 intravenous fluid resuscitation, DCQD jiajian intubation and decompression, laxative(glycerine enema
or folium sennae), intravenous fluid resuscitation
improvement of clinical manifestations
Peng T 2010 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, somatostatin, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, somatostatin
response rate, time to clinical/imaging manifestations
improved
Qiu JF 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian 50ml/12h
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, physiological saline
50ml/12h
time to first stool
Shen JQ 2005 intubation and decompression, intravenous fluid resuscitation, antibiotics,
glucocorticoids, omatostatin, CQD jiajian 200ml/d
intubation and decompression, intravenous fluid
resuscitation, antibiotics, glucocorticoids, somatostatin
improvement of clinical/imaging manifestations, time to
relief of symptome
Su SH 2008 DCQD jiajian(100ml/12h) primperan 2*10mg/d and mosapride 3*5mg/d improvement of clinical/imaging manifestations, time to
bowel open
Sui J 2010 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, somatostatin, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, somatostatin
improvement of clinical/imaging manifestations
Sun JJ 2006 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian 100ml/12h
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical manifestations, incidence of
complications
Tang ZA 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation, bowel rest, intubation and decompression, intravenous improvement of clinical manifestations
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antibiotics, DCQD jiajian fluid resuscitation, antibiotics
Tao YJ 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation
improvement of clinical/imaging manifestations
Tong FG 2006 bowel rest, intubation and decompression, intravenous fluid resuscitation,
DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, liquid paraffin
improvement of clinical manifestations
Wang CG
2010
analgesia, somatostatin, proton pump inhibitors, antibiotics,
glucocorticoids (dexamethasone), DCQD jiajian
analgesia, somatostatin, proton pump inhibitors,
antibiotics, glucocorticoids (dexamethasone)
improvement of clinical/imaging manifestations
Wang CH
2009
bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, somatostatin, proton pump inhibitors, DCQD jiajian
100ml/12h
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics, somatostatin, proton
pump inhibitors
improvement of clinical manifestations
Wang P 2007 anti-tuberculosis, bowel rest, intubation and decompression, intravenous
fluid resuscitation, DCQD jiajian
anti-tuberculosis, bowel rest, intubation and
decompression, intravenous fluid resuscitation
improvement of clinical/imaging manifestations
Wang W 2004 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
Wang YF 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
sandostatin, omeprazole, DCQD
bowel rest, intubation and decompression, intravenous
fluid resuscitation, sandostatin, omeprazole
improvement of clinical/imaging manifestations, time to
first flatus/stool, time to relief of abdominal pain, time to
first bowel movement, time to improvement of imaging
manifestations
Wen JY 2008 intubation and decompression, intravenous fluid resuscitation, antibiotics,
DCQD jiajian
intubation and decompression, intravenous fluid
resuscitation, antibiotics
improvement of clinical/imaging manifestations
Wu CT 2003 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
time to first stool, improvement of clinical/imaging
manifestations
Wu DH 2009 intubation and decompression, intravenous fluid resuscitation, antibiotics,
analgesia, DCQD
intubation and decompression, intravenous fluid
resuscitation, antibiotics, analgesia
improvement of clinical manifestations
Xie ZC 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
Xu HY 2009 bowel rest, intubation and decompression, intravenous fluid resuscitation,
octreotide, ranitidine, dexamethasone, diuretics, antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, octreotide, ranitidine,
dexamethasone, diuretics, antibiotics
time to first flatus, time to first bowel movement, time to
relief of symptom, improvement of clinical/imaging
manifestations
Yang SZ 2010 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
time to first flatus
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Ye B 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
You L 2008 bowel rest, intubation and decompression, intravenous fluid resuscitation,
soapsuds enema, antibiotics, DCQD jiajian, electro acupuncture
bowel rest, intubation and decompression, intravenous
fluid resuscitation, soapsuds enema, antibiotics
length of hospital stay, improvement of clinical
manifestations
Zhang Y 2007 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
Zhao Y 2006 bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, CQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
Zhao YL 2006 DCQD jiajian intubation and decompression, intravenous fluid
resuscitation, antibiotics
time to first flatus, time to first stool
Zheng HL
2010
bowel rest, intubation and decompression, intravenous fluid resuscitation,
antibiotics, DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation, antibiotics
improvement of clinical/imaging manifestations
Zhou SY 2009 bowel rest, intubation and decompression, laxatives (liquid paraffin),
intravenous fluid resuscitation, antibiotics, DCQD jiajian
bowel rest, intubation and decompression, laxatives
(liquid paraffin), intravenous fluid resuscitation,
antibiotics
improvement of clinical/imaging manifestations
Zhou YJ 2001 bowel rest, intubation and decompression, intravenous fluid resuscitation,
DCQD jiajian
bowel rest, intubation and decompression, intravenous
fluid resuscitation
improvement of clinical/imaging manifestations
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Figure 2: Effect of DCQD compared with conservative therapy in treatment of intestinal obstruction
DCQD, Da-Cheng-Qi decoction; 95% CI, 95% confidence interval
Note that Risk Ratio < 1 means numerically lower response rate than control group and RR > 1 numerically higher response rate than control group. 95% CI doesn’t include the number 1 means statistical difference
between the 2 groups.
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Figure 3: Forest plot of the time to first ﬂatus
SMD, standardised mean difference; 95% CI, 95% confidence interval
Note that SMD < 0 means numerically time to first ﬂatus in experiment group is shorter than control group and SMD > 0 numerically time to first 
ﬂatus in experimental group is longer than control group. 95% CI doesn’t include the number 0 means statistical difference between the 2 groups
Response to therapy in patients with mechanical intestinal obstruction
The 33 RCTs studying mechanical intestinal obstruction reported dichotomous data of 3,748 patients. Mechanical intestinal obstruction of
2,845 patients was caused by postoperative adhesion. Overall, 170 (8.4%) of 2,035 patients assigned to DCQD plus conservative therapy failed to
respond to therapy compared with 498 (29.1%) of 1,713 patients allocated to conservative therapy (RR of respond =1.26; 95% CI 1.21 to 1.31
which favoured DCQD plus conservative therapy) (Fig 4), with no significant heterogeneity between studies (I2=38%) and an NNT of 5.3 (95%
CI 4.5 to 5.9). There was no evidence of funnel plot asymmetry (Begg’s test, p=0.05).
Given the borderline heterogeneity observed when results of individual RCTs were combined, we conducted pre-specified sensitivity analyses
(Table 2). The RR of respond was relatively stable in all these analyses. Heterogeneity between trials was lower when only the 22 studies that
administrate DCQD via oral or when only the 12 studies that via rectal were included in the analysis. In addition, the results of sensitivity
analyses showed that DCQD administration via rectal seems to be more effective (NNT =4.2 95% CI 3.6 to 5.3). Treatment effect remained
similar when only the 23 trials at moderate risk of bias were considered.
Discussion
This systematic review and meta-analysis has demonstrated that DCQD plus conservative therapy were more effective than conservative
therapy alone for the treatment of intestinal obstruction, these beneficial effects appeared to exist for both ileus and mechanical intestinal
obstruction. In addition, DCQD administration via rectal seems to be more effective. The RR of respond was relatively stable in all the sensitivity
analyses. There was no statistical difference when we compared DCQD mono-therapy with conservative therapy alone. Although DCQD appear
to be more effective than conservative therapy when the only two studies using clinical manifestations and imaging test improvement to define
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response to treatment, considering there are only 60 subjects left in these two trials, we could draw no conclusion safely. For the continuous data
of the time to first flatus, we found that DCQD plus conservative therapy could significantly shorten the duration of postoperative ileus in patients
undergoing abdominal surgery.
Pharmacological studies and animal experiments have proved that effective components in DCQD could prevent intestinal adhesion by
reducing the concentration of fibrinogen and raising that of fibrin degrading products in the intro-abdominal exudates after major abdominal
surgery (Wang et al., 2004), and rhubarb in Radix et Rhizoma Rhei effects on colon (Jin et al, 2013) and increases the tension of it. Emodin can
enhance the function of small intestinal peristalsis by mechanisms of promoting secretion of motilin, lowering the content of somatostatin and
inhibiting sodium-potassium-exchanging ATPase activity of small intestinal mucosa (Zhang et al., 2005). Results of our research corroborated
these previous pharmacological studies and animal experiments from another angle.
This systematic review has several strengths. To our knowledge, this is the first meta-analysis that focuses on the efficacy and safety of DCQD
in the treatment of intestinal obstruction. The systematic review includes 60 RCTs with 6,095 patients, which makes it a powerful systematic
review to analyze the efficacy and safety of DCQD. The study population well represented the general intestinal obstruction population in terms
of age and pathogenesis. The success rate of conservative therapy alone was near to the previous study reported (Tanaka et al., 2008). We were
also rigorous in describing our search strategy, eligibility criteria, and data extraction processes in detail. We conducted subgroup analysis to
maintain clinical homogeneity in the patients, and sensitivity analyses according to risk of bias of included trials, route of administration,
deﬁnition of response to therapy and aetiology to assess whether any of these trial characteristics affected overall efficacy. We used an 
intention-to-treat analysis, where all drop-outs assumed to be treatment failures, and pooled data with a random effects model, in order to reduce
the likelihood that any beneficial effect of DCQD in intestinal obstruction has been overestimated.
Limitations of the present study, as with any systematic review and meta-analysis, arise from the quality and reporting of the RCTs included.
Methodologies of RCTs conducted in mainland China where various and some of the included RCTs did not report their results according to the
CONSORT checklist strictly. Blinding and allocation concealment were not reported in these RCTs, which means potential risk of bias. (Wood et
al., 2008; He et al., 2011). There was borderline heterogeneity when dichotomous data were pooled, but our sensitivity analyses revealed
plausible explanations for this. As for the significant heterogeneity when continuous data were pooled, the potential reasons may be the trials were
carried out by surgeons with different technical levels, and clinical background was various among the subjects included, thus clinical
heterogeneity inevitably existed. To perform subgroup analysis according to the type of surgical approach and the type of anaesthesia was
meaningful, but we could not do this because little trials reported results separately by detailed clinical backgrounds. However, this problem did
not prevent us from making a positive conclusion as other systematic reviews did.(Ford et al., 2009; Ford et al., 2011). Total adverse events data
for DCQD via oral or rectal were sparse, this, however, may because the side-effects of short-term use of DCQD were light (Zhang et al., 2008;
Maxion-Bergemann et al., 2006; Kaszkin-Bettag et al., 2008) and easily be overwhelmed by the primary diseases. Lack of long-term follow-up
prevented us from analysing the recurrence rate of intestinal obstruction.(Fevang et al., 2004) As limitations stated here, future well designed;
randomised; double-blind; multicentre; long-term follow-up studies are needed to investigate these unanswered questions.
In summary, current guidelines for the management of intestinal obstruction from national and international do not pay much attention to any
kinds of complementary and alternative medicine,(Diaz et al., 2008; Catena et al., 2011) evidence from this systematic review and meta-analysis
supports the use of DCQD plus conservative therapy, which may increase the success rate of conservative therapy significantly and shorten the
duration of postoperative ileus in patients undergoing abdominal surgery.
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Figure 4: Effect of DCQD plus conservative therapy compared with conservative therapy in treatment of intestinal obstruction
CT, conservative therapy; DCQD, Da-Cheng-Qi decoction; 95% CI, 95% confidence interval
Note that RR < 1 means numerically lower response rate than control group and RR > 1 numerically higher response rate than control group. 95%
CI doesn’t include the number 1 means statistical difference between the 2 groups.
References
1. Begg CB, Mazumdar M. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics. Dec;50(4):1088-101.
2. Catena F, Di Saverio S, Kelly MD, Biffl WL, Ansaloni L, Mandalà V, Velmahos GC, Sartelli M, Tugnoli G, Lupo M, Mandalà S, Pinna AD, Sugarbaker PH,
Van Goor H, Moore EE, Jeekel J. (2011). Bologna Guidelines for Diagnosis and Management of Adhesive Small Bowel Obstruction (ASBO): 2010
Evidence-Based Guidelines of the World Society of Emergency Surgery. World J Emerg Surg. Jan 21;6:5.
3. DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
4. Diaz JJ Jr, Bokhari F, Mowery NT, Acosta JA, Block EF, Bromberg WJ, Collier BR, Cullinane DC, Dwyer KM, Griffen MM, Mayberry JC, Jerome R. (2008).
Guidelines for management of small bowel obstruction. J Trauma. Jun;64(6):1651-64.
5. Fevang BT, Jensen D, Svanes K, Viste A. (2002). Early operation or conservative management of patients with small bowel obstruction? Eur J
Yang et al., Afr J Tradit Complement Altern Med. (2014) 11(4):101-119
http://dx.doi.org/10.4314/ajtcam.v11i4.17
119
Surg.168(8-9):475-81.
6. Fevang BT, Fevang J, Lie SA, Søreide O, Svanes K, Viste A. (2004). Long-term prognosis after operation for adhesive small bowel obstruction. Ann Surg.
Aug;240(2):193-201.
7. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. (2009). Efficacy of antidepressants and psychological therapies in irritable bowel syndrome:
systematic review and meta-analysis. Gut. Mar;58(3):367-78.
8. Ford AC, Suares NC. (2011). Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut.
Feb;60(2):209-18.
9. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. (2006). Recommendations for reporting randomized controlled trials of
herbal interventions: Explanation and elaboration. J Clin Epidemiol. Nov;59(11):1134-49.
10. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. (2006). Reporting randomized, controlled trials of herbal interventions:
an elaborated CONSORT statement. Ann Intern Med. Mar 7;144(5):364-7.
11. Gong H, Tang W, Wang H, Xia Q, Huang X. (2011). Effects of food and gender on the pharmacokinetics of rhein and emodin in rats after oral dosing with
Da-Cheng-Qi decoction. Phytother Res. Jan;25(1):74-80.
12. He J, Du L, Liu G, Fu J, He X, Yu J, Shang L. (2011). Quality assessment of reporting of randomization, allocation concealment, and blinding in traditional
Chinese medicine RCTs: a review of 3159 RCTs identified from 260 systematic reviews. Trials. May 13;12:122.
13. Jin R, Lin ZJ, Xue CM, Zhang B. (2013). An improved association-mining research for exploring Chinese herbal property theory: based on data of the
Shennong’s Classic of Materia Medica. J Integr Med. Sep;11(5):352-65.
14. Kaszkin-Bettag M, Richardson A, Rettenberger R, Heger PW. (2008). Long-term toxicity studies in dogs support the safety of the special extract ERr 731 from
the roots of Rheum rhaponticum. Food Chem Toxicol. May;46(5):1608-18.
15. Kumar S, Wong PF, Leaper DJ. (2009). Intra-peritoneal prophylactic agents for preventing adhesions and adhesive intestinal obstruction after
non-gynaecological abdominal surgery. Cochrane Database Syst Rev. Jan 21;(1):CD005080.
16. Markogiannakis H, Messaris E, Dardamanis D, Pararas N, Tzertzemelis D, Giannopoulos P, Larentzakis A, Lagoudianakis E, Manouras A, Bramis I. (2007).
Acute mechanical bowel obstruction: clinical presentation, etiology, management and outcome. World J Gastroenterol. Jan 21;13(3):432-7.
17. Maxion-Bergemann S, Bornhöft G, Sonderegger E, Renfer A, Matthiessen PF, Wolf U. (2006). Traditional Chinese medicine (phytotherapy): Health
Technology Assessment report - selected aspects. Forsch Komplementmed. 13 Suppl 2:30-41.
18. Moran BJ.. (2007). Adhesion-related small bowel obstruction. Colorectal Dis. Oct;9 Suppl 2:39-44.
19. Qi QH, Wang J, Hui JF. (2004). Effect of dachengqi granule on human gastrointestinal motility. Zhongguo Zhong Xi Yi Jie He Za Zhi. Jan;24(1):21-4.
20. Qi QH, Wang J, Liang GG, Wu XZ. (2007). Da-Cheng-Qi-Tang promotes the recovery of gastrointestinal motility after abdominal surgery in humans. Dig Dis
Sci. Jun;52(6):1562-70.
21. Satoh H. (2013). Pharmacological characteristics of Kampo medicine as a mixture of constituents and ingredients. J Integr Med. Jan;11(1):11-6.
22. Tanaka S, Yamamoto T, Kubota D, Matsuyama M, Uenishi T, Kubo S, Ono K. (2008). Predictive factors for surgical indication in adhesive small bowel
obstruction. Am J Surg. Jul;196(1):23-7.
23. Tang WF, Wan MH, Huang QR, Zhu ZY, Zhao JL, Wu YZ, Huang X. (2008). Effect of Da-Cheng-Qi decoction on the pharmacokinetics of ranitidine in rats.
Biomed Chromatogr. Aug;22(8):851-6.
24. Wang YL, Pan CE, Yang PL, Tian Y, Pei SW, Dong M. (2004). Effects of Antiadhesion preparation on free fibrinogen and fibrin degrading products in
abdominal exudates of rabbits postoperatively. World J Gastroenterol. Sep 15;10(18):2762-6.
25. Williams SB, Greenspon J, Young HA, Orkin BA. (2005). Small bowel obstruction: conservative vs. surgical management.. Dis Colon Rectum.
Jun;48(6):1140-6.
26. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. (2008) Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. Mar 15;336(7644):601-5.
27. Xu F, Liu Y, Dong H, Song R, Zhang Z. (2010). Pharmacokinetic comparison in rats of six bioactive compounds between Da-Cheng-Qi decoction and its
parent herbal medicines. Nat Prod Commun. May;5(5):795-800.
28. Zhang HQ, Zhou CH, Wu YQ. (2005). Effect of emodin on small intestinal peristalsis of mice and relevant mechanism. World J Gastroenterol. May
28;11(20):3147-50.
29. Zhang MJ, Zhang GL, Yuan WB, Ni J, Huang LF. (2008). Treatment of abdominal compartment syndrome in severe acute pancreatitis patients with traditional
Chinese medicine. World J Gastroenterol. Jun 14;14(22):3574-8.
